Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 4559-4570, June 15, 2008. doi: 10.1158/0008-5472.CAN-08-0021
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Jang, S.-W.
Right arrow Articles by Ye, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jang, S.-W.
Right arrow Articles by Ye, K.

Molecular Biology, Pathobiology, and Genetics

Serine/Arginine Protein–Specific Kinase 2 Promotes Leukemia Cell Proliferation by Phosphorylating Acinus and Regulating Cyclin A1

Sung-Wuk Jang1, Seung-ju Yang1, Åsa Ehlén3, Shaozhong Dong2, Hanna Khoury2, Jing Chen2, Jenny L. Persson3 and Keqiang Ye1

1 Department of Pathology and Laboratory Medicine and 2 Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia; and 3 Division of Pathology, Department of Laboratory Medicine, Lund University, University Hospital, Malmö, Sweden

Requests for reprints: Keqiang Ye, Emory University, Room 145, Whitehead Building, 615 Michael Street, Atlanta, GA 30322. Phone: 404-712-2814; Fax: 404-712-2979; E-mail: kye{at}emory.edu.

Key Words: SRPK2 • acinus • cyclin A1 • phosphorylation • cell proliferation

Serine/arginine (SR) protein–specific kinase (SRPK), a family of cell cycle–regulated protein kinases, phosphorylate SR domain–containing proteins in nuclear speckles and mediate the pre-mRNA splicing. However, the physiologic roles of this event in cell cycle are incompletely understood. Here, we show that SRPK2 binds and phosphorylates acinus, an SR protein essential for RNA splicing, and redistributes it from the nuclear speckles to the nucleoplasm, resulting in cyclin A1 but not A2 up-regulation. Acinus S422D, an SRPK2 phosphorylation mimetic, enhances cyclin A1 transcription, whereas acinus S422A, an unphosphorylatable mutant, blocks the stimulatory effect of SRPK2. Ablation of acinus or SRPK2 abrogates cyclin A1 expression in leukemia cells and arrest cells at G1 phase. Overexpression of acinus or SRPK2 increases leukemia cell proliferation. Furthermore, both SRPK2 and acinus are overexpressed in some human acute myelogenous leukemia patients and correlate with elevated cyclin A1 expression levels, fitting with the oncogenic activity of cyclin A1 in leukemia. Thus, our findings establish a molecular mechanism by which SR splicing machinery regulates cell cycle and contributes to leukemia tumorigenesis. [Cancer Res 2008;68(12):4559–70]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.